source
- Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trialA Phase 3 study of a personalized mRNA vaccine for melanoma, developed by Merck and Moderna, showed a substantial improvement in patient outcomes. Patients receiving the vaccine together with Merc…
- AstraZeneca highlights broad oncology portfolio at ESMO conferenceAt the European Society for Medical Oncology (ESMO) meeting in Madrid, AstraZeneca used the platform to showcase its cancer research. The company presented data on both established medicines and n…